New Peer Reviewed Publication of Combination Therapy in Vitiligo with STRATA Skin Sciences’ Excimer Laser and JAK Inhibitors Demonstrated Superior Safety and Unprecedented Response Rates, Providing Continued Validation of Personalized Medicine Approach

Core Insights - STRATA Skin Sciences, Inc. has published a study confirming the superiority of its 308nm Excimer laser combined with a JAK inhibitor over monotherapy, indicating significant market growth potential and expanded treatment indications [1][2][4] Study Findings - The study involved 251 patients and demonstrated five key findings regarding the combination therapy: 1. Mechanistic synergy between JAK inhibitors and Excimer laser promoting effective treatment [6] 2. Superior efficacy with a 14.20% higher repigmentation rate compared to monotherapy [6] 3. Unprecedented response rates with a 100% significant efficacy rate after 52 weeks of treatment [6] 4. Durable stability with a 96.5% pigmentation stability rate and an 8.8% relapse rate at one-year follow-up [6] 5. Excellent safety profile with no serious or persistent adverse events reported [6] Clinical Validation - The study adds to over 400 existing studies validating the efficacy of the 308nm Excimer laser as a cornerstone therapy for various dermatologic conditions, including vitiligo and psoriasis [3][4] Market Position - STRATA's Excimer laser technology has been in use for around 20 years, and dermatologists continue to rely on its performance for durable repigmentation in challenging skin conditions [2][4] Future Directions - The company is pursuing expanded reimbursement for its treatment modalities and aims to provide broader access by early 2026 [3]